Burak OKUMUS, Kader Semra KARATAS, Asli Enzel KOC

A serious dermatological side effect due to vortioxetine: a case report

Major depressive disorder is the second-largest healthcare problem worldwide in terms of illness-induced disability, and second-generation antidepressants are the most commonly used treatments in this disorder. Vortioxetine is a recently introduced antidepressant with a multimodal mechanism of action. Some side effects associated with the use of vortioxetine have been reported. Side effects that do not occur in clinical trials can be reported during phase IV studies. In this case report, we present a patient who developed dermatological adverse reactions following vortioxetine use.

PDF

___

1. Sagud M, Nikolac Perkovic M, Vuksan-Cusa B, Maravic A, Svob Strac D, Mihaljevic Peles A, et al. A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. Psychopharmacology (Berl) 2016; 233:3259-3267.

2. Sowa-Kućma M, Pańczyszyn-Trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, et al. Vortioxetine: a review of the pharmacology and clinical profile of the novel antidepressant. Pharmacol Rep 2017; 69:595-601.

3. Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry 2015; 76:575-582.

4. Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, et al. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016; 30:242-252.

5. Cetin M, Kose S. Serious dermatological adverse effects of vortioxetine: Two cases. Psychiatry and Clinical Psychopharmacology 2018; 28:355-357.

6. Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol 2015; 19.

7. Theunissen EL, Street D, Højer AM, Vermeeren A, van Oers A, Ramaekers JG. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther 2013; 93:493-501.

8. Subeesh V, Singh H, Maheswari E, Beulah E. Novel adverse events of vortioxetine: a disproportionality analysis in USFDA adverse event reporting system database. Asian J Psychiatr 2017; 30:152-156.

9. Ay R, Aytas O. Acneiform eruption associated with the use of vortioxetine. Psychiatry and Clinical Psychopharmacology 2019; 29:226-228. (Turkish)

10. Herstowska M, Komorowska O, Cubała WJ, Jakuszkowiak-Wojten K, Gałuszko-Węgielnik M, Landowski J. Severe skin complications in patients treated with antidepressants: a literature review. Postepy Dermatol Alergol 2014; 31:92-97.

11. Shah B, Levenson JL. Use of psychotropic drugs in the dermatology patient: when to start and stop? Clin Dermatol 2018; 36:748-755.

12. Ford HE, Jenike MA. Erythema multiforme associated with trazodone therapy. J Clin Psychiatry 1985; 46:294-295.

13. Khan MAU, Fitzgerald K. Low dose sertraline induced erythema multiforme in a child. J Child Adolesc Psychopharmacol 2012; 22:179-180.

14. Kohn S, Labbate LA. Venlafaxine and Ecchymosis. Can J Psychiatry 1997; 42:91.

15. Sarma A, Horne MK 3rd. Venlafaxine induced ecchymoses and impaired platelet aggregation. Eur J Haematol 2006; 77:533-537.

16. Kocbiyik S, Batmaz S, Turhan L, Yuncu OA, Caykoylu A. Resolution of ecchymotic lesions due to fluoxetine and escitalopram after introduction of reboxetine. Cukurova Med J 2015; 40(Suppl 1):90-93. (Turkish)

17. Calhoun JW, Calhoun DD. Prolonged bleeding time in a patient treated with sertraline. Am J Psychiatry 1996; 153:443.

18. Vandel P, Vandel S, Kantelip JP. SSRI induced bleeding: two case reports. Therapie 2001; 56:445-447.

19. Akbulut S, Yagmur Y, Gumus S, Babur M. Breast ecchymosis: Unusual complication of an antidepressant agent. Int J Surg Case Rep 2014; 5:129-130.

20. Gahr M, Zeiss R, Lang D, Connemann BJ, Hiemke C, Muche R, et al. Association between haemorrhages and treatment with selective and non-selective serotonergic antidepressants: Possible implications of quantitative signal detection. Psychiatry Res 2015; 229:257-263.

21. Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment 2018; 11:48-59.